首页> 外文会议>St. Gallen EORTC Gastrointestinal Cancer Conference >Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients
【24h】

Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients

机译:在410个新辅助治疗胃癌患者中仅包括Prethereic参数的分数预测响应和预后预测

获取原文

摘要

Introduction: Response to neoadjuvant chemotherapy (NAC) is an independent prognostic factor in locally advanced gastric cancer. However, no prospectively tested pretherapeutic parameters predicting response and/or survival in gastric cancer are available in clinical routine. Patients and methods: We evaluated the prognostic significance of various clinicopathologic parameters in 410 patients who were treated with NAC followed by gastrectomy. Clinical and histopa-thological response evaluation was performed using standardized criteria. A prognostic score was created on the basis of the variables identified in the multivariate analysis. Results: Multivariate analysis identified three pretherapeutic parameters as positive predictive factors for response and prognosis: tumor localization in the middle third of the stomach (p = 0.001), well differentiated tumors (p = 0.001) and intestinal tumor type according to Lauren's classification (p = 0.03). From the obtained data a prognostic index was constructed, dividing the patients into three risk groups: low (n = 73), intermediate (n = 274), and poor (n = 63). The three groups had significantly different clinical (p = 0.007) and histopathological response rates (p = 0.001) and survival times, with a median survival time that was not reached in the low-risk group, 39.2 months in the intermediate-risk group and 20.5 months in the poor-risk group. The corresponding 5-year survival rates were 65.3, 41.2, and 21.2 % (p < 0.001), respectively. Conclusion: A simple scoring system based on three clinicopathologic parameters, accurately predicts response and prognosis in neoadjuvant treated gastric cancer. This system provides additional useful information that could be applied to select gastric cancer patients pretherapeutically for different treatment approaches. Prospective testing of the score in an independent patient cohort is warranted.
机译:简介:对Neoadjuvant化疗(NAC)的反应是局部晚期胃癌的独立预后因素。然而,在临床常规中可以没有预测胃癌中的响应和/或存活的前瞻性测试的前瞻性参数。患者及方法:我们评估了410例患者治疗NAC后的各种临床病理学参数的预后意义,其次是胃切除术。使用标准化标准进行临床和组织族抗性评估。在多变量分析中识别的变量的基础上创建了预后分数。结果:多变量分析确定了三种抗议预测因子的三种蛋白酶参数:胃中间三分之一的肿瘤定位(P = 0.001),良好的分化肿瘤(P = 0.001)和肠肿瘤类型根据Lauren的分类(P = 0.03)。从所得数据构建预后指数,将患者分成三个风险群:低(n = 73),中间体(n = 274),差(n = 63)。三组具有显着不同的临床(P = 0.007)和组织病理学反应率(P = 0.001)和存活时间,中间风险组39.2个月内未达到中位生存时间,并入贫困风险集团20.5个月。相应的5年生存率分别为65.3,41.2和21.2%(P <0.001)。结论:基于三个临床病理学参数的简单评分系统,准确预测新辅助治疗胃癌的响应和预后。该系统提供了额外的有用信息,可以应用于为不同的治疗方法选择胃癌患者。有必要对独立患者群组中得分的预期测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号